BLOG
The success factors behind the success story of Mablink, a French ADC company to be acquired by Lilly
The disclosed factors and the non-disclosed price explained by a previous SAB member
Carl Vogt et Eric Bauce : choix controversé de recteurs
En 1874, Carl Vogt devint le premier Recteur de la nouvelle Université de Genève. En 2023, Eric Bauce, choisi par l’Assemblée de l’Université, en deviendra peut-être le nouveau Recteur. Il est frappant de voir le télescopage des controverses avec deux personnalité.
Carl Vogt : un anthropologue de son siècle, comme Charles Darwin
La récente décision de débaptiser un bâtiment Uni Carl Vogt à Genève donne l’occasion de redécouvrir les diverses facettes de l’œuvre de Carl Vogt au-delà de son héritage raciste et misogyne.
La résilience de la démocratie américaine grâce aux élections des Secrétaires d’Etat
Brad Raffensperger, Secrétaire d’Etat de Géorgie devint connu internationalement lorsqu’il refusa de « trouver » 11’780 votes lors d’un appel avec le Président Trump.
Ce sujet d’élection américaine est à l’évidence en dehors des sciences de la vie mais les lecteurs verront à la fin le lien avec Genève et un engagement plus personnel de votre serviteur.
Se vacciner à nouveau contre le COVID, le choix de la cigale ou de la fourmi ?
Un deuxième booster anti-COVID après le premier est recommandé pour les personnes à risque. Depuis peu les autres personnes éligibles à ce rappel doivent payer de leur poche en Suisse.
NEWS
TheraPPI Bioscience Awarded Reputable French Tech Seed Label
The Pouss@LYS consortium has recently given a favorable recommendation on French Tech Seed label to TheraPPI
TheraPPI Bioscience awarded a Fongit Innovation Fund (FIF) seed loan
THERAPPI BIOSCIENCE HAS BEEN AWARDED A FONGIT INNOVATION FUND (FIF) SEED LOAN
TheraPPI Bioscience announces an exclusive license agreement with PULSALYS to develop novel drugs in oncology and rare diseases
PULSALYS and TheraPPI Bioscience SAS enter into an exclusive and global license agreement to develop drugs targeting a novel Ras-MAPK pathway protein interaction
Mablink Bioscience Enters an Agreement to be Acquired by Lilly
Mablink today announced an agreement to be acquired by Eli Lilly and Company.
NETRIS Pharma announces data published in two Nature papers confirming netrin-1 blockade as significant clinical strategy in oncology
NETRIS Pharma publishes two back-to-back papers in Nature journal on NP137 being effective in reducing tumor growth and inhibiting tumor epithelial-to-mesenchymal transition (EMT).
Mablink Bioscience appoints Pejvack Motlagh, M.D., as Chief Medical Officer
Mablink appoints Pejvack Motlagh, M.D., as CMO who will serve on the Executive Management Team and report directly to Mablink’s CEO.
TheraPPI to present at Event BioValley Basel – Business Angel Chapter
TheraPPI’s CEO will present at BioValley Basel on 19 June 2023.
TheraPPI to present at TechTour in Paris
TheraPPI’s CEO will present at TechTour in Paris on 2nd June 2023.
TheraPPI among the Finalists of the 2023 >>venture>>
TheraPPI Bioscience is finalist of 2023 >>venture>>, a highly competite startup challenge.
NETRIS Pharma Doses First Patient in Pancreatic Cancer Clinical Study with NP137
NETRIS Pharma initiates Lap-NET1, a multicenter, prospective, single arm, proof-of-concept trial of NP137, in combination with mFOLFIRINOX in first line patients with locally advanced pancreatic ductal adenocarcinoma.
Mablink Bioscience to Present Promising Preclinical Data for Lead ADC Candidate MBK-103 at the AACR
Mablink will present preclinical efficacy and safety data on its lead program, MBK-103, at the AACR Meeting 2023 on April 17, 2023, in Orlando, Florida.
NETRIS Pharma Doses First Patient in Hepatocellular Carcinoma (HCC) Clinical Study with NP137
NETRIS Pharma initiates Liver-NET1, a multicenter, prospective, single arm, proof-of-concept trial of NP137, in combination with atezolizumab-bevacizumab in first line patients with advanced hepatocellular carcinoma.